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Background: Despite the increased availability of anti-retroviral therapy, in-hospital HIV mortality remains high in
sub-Saharan Africa. Reports from Senegal, Malawi, and Tanzania show rates of in-hospital, HIV-related mortality
ranging from 24.2% to 44%. This mixed methods review explored the potential causes of preventable in-hospital
mortality associated with HIV infections in sub-Saharan Africa in the anti-retroviral era.
Results: Based on our experience as healthcare providers in Africa and a review of the literature we identified 5
health systems failures which may cause preventable in-hospital mortality, including: 1) late presentation of HIV
cases, 2) low rates of in-hospital HIV testing, 3) poor laboratory capacity which limits CD4 T-cell testing and the
diagnosis of opportunistic infections, 4) delay in initiation of anti-retroviral therapy in-hospital, and 5) problems
associated with loss to follow-up upon discharge from hospital.
Conclusion: Our findings, together with the current available literature, should be used to develop practical
interventions that can be implemented to reduce in-hospital mortality.
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The aim of the literature review is to explore the poten-
tial causes of preventable in-hospital mortality associated
with HIV infections in sub-Saharan Africa in the anti-
retroviral era, and to discuss possible health systems im-
provements that may reduce this mortality. This review
focuses on the in-hospital deaths that could be prevented
with the current knowledge and resources available in
many hospitals in sub-Saharan Africa. We recognize that a
substantial number of HIV-related deaths in sub-Saharan
Africa occur among community dwelling individuals who
do not have access to care and medications. However, we
are specifically interested in deaths in areas where HIV
testing, opportunistic infection (OI) treatment, and anti-* Correspondence: wajangabmk@gmail.com
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unless otherwise stated.retroviral treatment (ART) are available, and yet break-
downs in the health system lead to AIDS-related deaths.
Studies in sub-Saharan Africa have documented the high
rates of in-hospital fatality due to HIV. The Infectious
Diseases Clinic of Fann Teaching Hospital in Dakar,
Senegal, saw an in-hospital fatality rate of 44% among
HIV-positive admitted individuals [1]. In 2004, Kamuzu
Central Hospital (KCH) in Malawi gained access to free
ART and yet in 2008 and 2009, a study found the mor-
tality rate of HIV-positive individuals admitted to KCH
was 24.2% [2]. Despite these high levels of in-hospital
mortality, little information currently exists on causes
of in-hospital HIV deaths in sub-Saharan Africa and
how to prevent them.
Our own experience at Bugando Medical Centre has
been similar. Bugando is a tertiary referral and teaching
hospital that serves the Lake Victoria region of north-
western Tanzania (population: 13 million). BMC is lo-
cated in the city of Mwanza, the second largest urban
center in Tanzania and the capital of the Mwanza region.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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two male and two female. The HIV prevalence in the
Mwanza region is approximately 6%, and ART has been
provided free of charge at BMC since 2007. Despite the
availability of ART, HIV still accounts for 22% of all of
our medical admissions and 33% of all deaths on the
medical wards, and the in-hospital mortality rate for
adults admitted with HIV is 28.6% [3].
Health care delivery systems in sub-Saharan Africa still
face numerous challenges in decreasing HIV/AIDS mor-
tality despite the increase in availability of ART for those
who are eligible. In June 2001, a United Nations General
Assembly Special Session (UNGASS) on HIV/AIDS was
held in New York with the goal of uniting countries to
address the problem of HIV/AIDS. The assembly recog-
nized the urgency of the epidemic and secured a global
commitment to universal access to HIV/AIDS care [4].
The Global Fund and the US President’s Emergency Plan
for AIDS Relief (PEPFAR) were soon created. The
Global Fund became a major financer of programs that
fight HIV/AIDS, tuberculosis, and malaria, and PEP-
FAR provided increased funding in sub-Saharan Africa
for the roll-out of HIV services including anti-retroviral
therapy [5].
There are nearly 34 million people worldwide with
HIV, of which, approximately 22.5 million reside in sub-
Saharan Africa [6,7]. In 2011, about 6.2 million people in
sub-Saharan Africa had access to antiretroviral therapy –
that is slightly over half of the individuals who are eli-
gible and an increase of over 1 million individuals com-
pared to the previous year [5]. For those with access to
ART, HIV no longer needs to be a death sentence. A re-
cent study showed that life expectancy of HIV-positive in-
dividuals in the US who begin ART approaches the life
expectancy of HIV-negative individuals [8]. The efficacy of
combination ART has improved, and access to ART has
increased drastically; therefore, in many settings drug effi-
cacy and lack of drugs can no longer be blamed for the
high rates of in-hospital mortality.
Therefore, we conducted a mixed methods review [9]
in which we used observations from our experience withFigure 1 Potential health systems failures leading to preventable in-hHIV-infected adults at BMC to define 5 preventable
causes of in-hospital mortality associated with HIV in-
fections in sub-Saharan Africa (see Figure 1). We then
used narrative review to further characterize each of
these barriers and to explored possible interventions
which may be used to reduce in-hospital mortality.
Review
Late presentation in hospital
Observation #1
At BMC we have observed that only 45% of HIV-
positive patients admitted to our wards knew their HIV
status before admission. The remaining 55% are new
HIV diagnoses made in-hospital, and opportunistic in-
fections were the catalyst to obtain HIV testing for al-
most all of these patients.
Late presentation plays a major role in AIDS related
in-hospital deaths in sub-Saharan Africa. Many individ-
uals in sub-Saharan Africa do not access HIV testing
and care until they develop opportunistic infections and
reach an advanced stage [10]. Table 1 summarizes six stud-
ies from sub-Saharan Africa which consistently show pa-
tients with HIV/AIDS presenting with a CD4 count <200
and an advanced stage. The median CD4 count of newly
diagnosed HIV patients was less than 100 cells/μL. Studies
from numerous countries in sub-Saharan Africa have re-
ported similarly high rates of late diagnosis of HIV, or late
presentation of HIV infection in hospitals or late presenta-
tion for ART treatment.
Late presentation has been linked with higher mortal-
ity. A study in Brazil recently found that 44.8% of pa-
tients who had HIV were diagnosed either during their
first hospitalization or less than 30 days prior to
hospitalization for an AIDS related illness. For patients
diagnosed with HIV at the time of hospitalization from
an AIDS related condition, the 12 month survival prob-
ability was only 48% [11].
Barriers such as stigma, education, fear of HIV status,
long-travel distance to HIV testing sites, lack of confi-
dentiality and delay in test results limit patients’ access
to HIV testing [12-19]. Alternative methods of voluntaryospital HIV/AIDS mortality in Africa.
Table 1 Late presentation to health care facilities of HIV AIDS patients in sub Saharan Africa
Reference Country Late stage presentation Patient Population
Bassett, et al. South Africa Median CD4 count of 96 cells/uL Median CD4 count of patients when deemed ART eligible (not
ART initiation) at the Sinikithemba HIV clinic at McCord Hospital.
Mulissa, et al. Ethiopia Median CD4 value 156 cells/mm3,
WHO stage III (49.2%),
WHO stage IV (13.3%)
Values of all adult HIV-positive patients at time of presentation
to care at Arba Minch Hospital.




Mean CD4 values was 100/mm3,
CD4 cell lymphocytes ≤ 200 in 86%
of cases, AIDS diagnosis in 88%
of admitted patients
All HIV-positive patients hospitalized in the Infectious Diseases
Clinic of Fann Teaching Hospital in Dakar.
Amuron, et al. Jinja, Uganda Median CD4 value was 157/mm3
(patients screened between
January 6 and December 6, 2005)
HIV-infected subjects being tested for ART eligibility after
HIV-diagnosis at The AIDS Support Clinic.
Ingle, et al. South Africa Median CD4 value was 101/mm3 in
2007
Initial CD4 screening in HIV-infected patients from 36 facilities
participating in the Comprehensive HIV and AIDS Management







Median baseline* CD4 value was
122 cells/mm3 in 2005–2006 in Africa**
HIV-infected patients from numerous health facilities throughout
sub-Saharan Africa**.
*Measurements of laboratory values closest to the starting date of ART (within 6 months before up to one week after the date of starting ART) were taken as the
baseline levels. For very low CD4 values (<25 cells ⁄ll) and high HIV viral loads (>100 000 copies ⁄ ml) the time window was extended to one year before
starting therapy.
**Sites of evaluation from (1) Abidjan, Cote d’Ivoire, (2) Dakar, Senegal, (3) Eldoret, Kenya, (4) Kampala, Uganda, (5) Mbarara, Uganda, (6) Lilongwe, Malawi,
(7) Cape Town, South Africa, (8) Johannesburg, South Africa, (9) Soweto, South Africa.
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counseling and testing’ (VCT) clinics and home-based
VCT should be employed to increase the number of in-
dividuals being tested for HIV. A review by Matovum
et al. showed that both alternative methods of VCT can
help overcome barriers to early HIV testing [16]. A study
by Sweat et al. demonstrated that community mobilization
activities can assist in increasing VCT uptake compared to
standard clinic-based VCT [20]. HIV testing cannot be
limited to a few highly specialized medical centers, but
must be made available locally and in a variety of different
community-based settings.
Low rates of in-hospital HIV testing
Observation #2
On the wards of BMC, through continuous quality im-
provement we have been able to improve our HIV test-
ing rates from 10% to 50%. Despite our best efforts,
though, we have not been able to consistently achieve
HIV testing rates greater than 50%.
Another contributor to in-hospital mortality is a delay
or lack of in-hospital HIV testing. To increase the num-
ber of individuals who are aware of their HIV serostatus,
in 2007 the WHO announced recommendations to offer
routine HIV testing in clinical settings now known as
‘provider-initiated testing and counseling’ (PITC). Under
the PITC model, providers should recommend testing to
every patient who enters a health facility, regardless of
the purpose of the visit [21]. Although PITC was unable
to achieve 100% HIV testing in the studies identified,research still supports PITC as an effective intervention
to increase HIV testing. A controlled trial in Cape Town,
South Africa, found that after PITC was implemented,
the proportion of patients at the sexually transmitted in-
fections (STI) clinic who received an HIV test increased.
Furthermore, PITC made the level of HIV testing more
consistent across the sexually transmitted infection (STI)
clinics in the area [22]. Another evaluation of PITC in
South Africa showed PITC increased HIV testing in pa-
tients when compared to voluntary counseling and testing
[23]. When PITC was implemented at the Baylor Inter-
national Pediatric AIDS Initiative (BIPAI) in Tanzania,
81% of all pediatric admissions either tested for HIV or
provided valid HIV test results, an increase from only
33.3% with non-routine HIV testing [24]. Lastly, a review
of PITC in low- and middle-income countries found that
after PITC was implemented, HIV testing increased. Of
note, in most studies condom use also increased after
PITC. The studies found few negative outcomes, and
therefore support PITC implementation and scale-up to
increase HIV testing [25]. The authors also concluded that
strong leadership was necessary to fully implement the
PITC model in high-burden settings.
In some settings, the introduction of PITC has not
been successful. PITC was introduced in Tanzania in
2007 after the WHO’s recommendation, but despite
PITC, only 10% of all Tanzanians knew their HIV status
in 2009 [26]. In Blantyre, Malawi after national recom-
mendations for PITC, prospective analysis showed that
of the 18,021 adults who attended the clinic from
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testing and counseling [27]. A review of PITC imple-
mentation in sub-Saharan Africa by Roura et al. found
that the percentage of the target group who were of-
fered an HIV-test by healthcare providers ranged from
24% in an Ethiopian study to 94% in a study from South
Africa [28-30].
To assess the barriers to PITC implementation, a
cross-sectional study was conducted in 2010 in the gov-
ernment health facilities of Mbeya City Council in
Southern Tanzania. All 402 health care providers inter-
viewed had heard of PITC. While the majority of health
workers (65.2%) had positive feelings about PITC, 63.2%
also felt PITC took too much time and was too involved
for them. The majority, 77.9%, of health workers felt
PITC should only be offered for patients at high risk of
HIV infection, focusing more efforts on STI clinics and
symptomatic patients. The most commonly reported
obstacle to implementing PITC by health workers was
that HIV testing did not seem relevant to the patient’s
visit (61%). Other perceived barriers were too few health
care workers (42.8%), too many patients (57.7%), lack of
PITC training (46.5%), and test kit shortages (37.1%)
[31]. Roura, et al. also examined the factors indicated by
healthcare providers for not implementing PITC. The
two main points were fear of offending patients by offer-
ing HIV testing and a perceived slowing of patient care
in the clinic [28].
In examining the impact of PITC on limited human
resources, one study in Kenya found that implementing
PITC increased the median consultation time from 10 to
17 minutes [32]. Another study in Zambia showed that
patient-provider contact time increased by 55% after
PITC was implemented [33]. Several areas have tried to
address the impact of PITC on human resources by
using trained lay counselors and assistant physicians to
conduct PITC [33,34]. A group in South Africa tried to
optimize human resources by conducting group pre-test
counseling sessions (keeping the option of individual
sessions if desired by patients) [35]. More research needs
to be conducted on how to use existing human resources
to efficiently and effectively implement PITC in-hospitals
with the current human resources and to overcome per-
ceived and real barriers that prevent health care workers
from fully implementing this procedure.Laboratory capacity and delayed OI diagnosis and treatment
Observation #3
At BMC, despite the fact that CD4 count is requested
for all HIV patients and is required for initiation of ART
in a patient, less than 20% of patients receive results
during hospitalization, and the turnaround time is an
average of five days.Low laboratory capacity was also identified as a cause
of in-hospital mortality, leading to delayed CD4 testing
and OI diagnosis and treatment. CD4 testing is import-
ant for patient care in order to monitor patients and to
determine who is eligible to initiate ART, but it requires
a flow cytometer which is not routinely available in
many laboratories in the developing world [36]. Further-
more, even when available many existing laboratory in-
struments end up non-functional or without reagents
for testing [37]. For example, between 2009 and 2010 in
Malawi, only 52 of the 396 ART sites (13%) had CD4
flow cytometers, and of the 52 machines, 10 (20%) of
the CD4 machines in the country were not functional
[38]. Technologically, CD4 machines are complex, re-
quiring regular maintenance, a steady stock of reagents,
and skilled staff [36]. Laboratory staff shortages for CD4
testing become even more apparent when VCT or PICT
interventions are scaled up in high-prevalence contexts.
The number of identified HIV patients in need of CD4
tests increases and strains the already limited laboratory
resources [36]. Advances in point-of-care CD4 testing
with simplified technology offer an opportunity to both
expand access and increase the speed of CD4 tests.
As noted, low laboratory capacity also leads to delays in
OI diagnosis and treatment. A review of tuberculosis, a
common opportunistic infection, demonstrates these de-
lays. Studies in Uganda, Botswana, Malaysia and Ethiopia
found median health system delays for TB diagnosis ran-
ging from 4 to 12 weeks [39-43]. One study in Nairobi,
Kenya, showed a very high level of under-diagnosis of
smear positive tuberculosis; of individuals who had pre-
sumed smear negative pulmonary tuberculosis, 26% had
smear positive results when re-examined carefully with re-
peat sputum smears [44]. In our experience in Tanzania,
delays in collecting sputum samples in hospitalized pa-
tients and then retrieving lab results can cause a 7–10 day
delay between admission and diagnosis of smear-positive
tuberculosis. Delays in diagnosis and treatment for tu-
berculosis lead to increased morbidity and mortality
[39]. Though little research has been done on diagnosis
and treatment delays of other opportunistic infections
in resource-poor settings, we believe tuberculosis is a
good example of the delays that may be happening in
the diagnosis and treatment of other opportunistic
infections.
Shortage of laboratory personnel, limited funding, and
limited technical support are some reasons noted for
constraining expansion of necessary diagnostic testing
and limiting laboratory capacity in sub-Saharan Africa
[45,46]. The severe shortage of laboratory personnel in
many developing countries is the result of limited profes-
sional training and accreditation programs [45]. Although
accurate diagnostic tools are necessary to monitor HIV/
AIDS progression and opportunistic infections, laboratory
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funding as clinic activities [46].
In 2010, the WHO of the African region recognized
the need for laboratory capacity building, and outlined a
series of actions that need to be taken to bolster labora-
tory capacity in Africa. This includes the development of
a comprehensive national laboratory policy with a national
laboratory strategic plan, laboratory leadership, funding
sources, national reference laboratory, laboratory supply
and distribution systems, and quality assurance [47].
Delay in initiation of ART in-hospital
Observation #4
At BMC, even though most HIV-positive hospitalized
patients at BMC may qualify to begin ART either based
on CD4 counts (mean CD4 count of 248 cells/mm3) or
presence of an opportunistic infections like tuberculosis,
still <1% of HIV positive patients are initiated on ART
in the wards.
Another preventable health system failure that con-
tributes to HIV-related in-hospital deaths is the delay in
initiating ART. Early ART initiation in AIDS patients is
important for survival. Bekker et. al noted that if an indi-
vidual who is first diagnosed as HIV-positive is already
at the AIDS stage of the disease, the ART eligibility
threshold has previously been crossed. The review then
found that each ensuing month’s delay in initiating ART
treatment after presenting in a health system with an
AIDS diagnosis increases mortality 4–8% [10].
Another randomized trial performed in Haiti found that
early ART-initiation (>200 and <350 CD4 T-cells per mm3)
compared to ART initiation at a CD4 T-cell count <200 de-
creased the rates of death by 75% and incident tuberculosis
by 50%, leading the WHO to revise ART treatment initi-
ation guidelines from 200 to 350 cells/mm [48]. Overall,
prompt ART initiation once HIV status and ART eligibility
are determined increases life expectancy compared to de-
layed ART initiation [10,48-51].
Numerous studies have documented the impact of
early initiation of ART in newly diagnosed HIV-infected
patients who present with tuberculosis. Findings in one
study in South Africa showed that the incidence of death
was significantly less in patients with a CD4 count less
than 50 cells/mm3 when ART treatment was started
within 4 weeks of the initiation of tuberculosis treatment
versus starting ART later (within 4 weeks of the continu-
ation phase of TB treatment) [52]. Another study by
Havlir, et al. found that for individuals with CD4+
counts less than 50 cells/mm3, immediate ART initiation
(within 2 weeks of starting TB therapy) led to 42% less
AIDS illnesses or deaths than ART initiation 8–12 weeks
after TB treatment initiated [53]. Similarly, in Cambodia,
Blanc, et al. found that patients with a CD4 count less
than 200 cells/mm3 who started ART within 2 weeks ofTB treatment initiation experienced significantly better
survival rates than those who started ART 8 weeks after
TB treatment initiation [54].
In undiagnosed patients presenting in hospital with
OIs, initiating ART during OI treatment resulted in bet-
ter outcomes than waiting to begin ART. Zolopa, et al.
found that patients who began ART during OI treatment
had significantly lower levels of AIDS progression and
death than the patients that waited until completing OI
treatmentto begin ART [55]. More specifically, this study
demonstrated that in a cohort of very sick HIV-infected
patients that presented to hospitals with OIs and a mean
CD4 count of 47 cells/mm3, initiating ART simultan-
eously with OI treatment significantly decreased death
and AIDS progression versus waiting 1 month after OI
treatment initiation to begin ART [55,56].
Though early ART initiation has been proven to have
positive impacts on patient outcomes, there is a lack of
integration between HIV testing and initiation in hospi-
tals. The lack of integration was illustrated in a retro-
spective study from Kamuzu Central Hospital in Malawi.
Although over 85% of patients identified as HIV-infected
were already ART-eligible during hospitalization, none
started ART in hospital [24].
Loss to follow-up (LTFU) upon discharge from hospital
Observation #5
At BMC, the lack of integration of HIV clinics to pri-
mary care services has made follow-up of these patients
after discharge from hospital difficult. Our patients stay
in the hospital an average of one week, and on discharge
are advised to attend the nearest HIV clinic of their
choice. Due to mixed feelings such as denial and stigma
associated with HIV, many patients delay seeking help at
HIV clinics and hence re-present to hospitals only when
they develop new or recurrent opportunistic infections.
Many HIV-infected individuals are lost to follow up
after their hospital stay. Patients lost to follow-up have
higher mortality than those who remain in an HIV care
and treatment program, and may re-present to hospitals
in the future at an advanced disease stage with high rates
of mortality. Data collected through the National Care
and Treatment database in Tanzania was used to analyze
HIV care and LTFU in 88,875 adults from 101 clinics in
Tanzania. This analysis found that 12 months after ART
treatment initiation, 18% of adults had already been lost
to follow-up. After 36 months, 36% had been lost to
follow-up [57]. Another review of patient retention in
sub-Saharan Africa found that after 2 years of treatment,
only 60% of patients were retained in HIVART care [58].
Such failure or delay in outpatient care linkage is wide-
spread and has been well documented. In Ethiopia, re-
ports from the Ministry of Health from 2005 to 2008
showed that only 61% of patients newly diagnosed with
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lethu outpatient ART program in Cape Town, 66% of
deaths actually occurred within 90 days of pre-ART en-
rollment in the patients who were awaiting ART initi-
ation. Overall, this study demonstrated that the health
system failure resulting in a 3-month delay of ART led
to a substantial number of deaths in patients with severe
immune suppression [60].
Exact causes of LTFU are often difficult to understand
and not well documented. A review of patients LTFU in
ART-treatment programs in resource-limited settings
found that 83% of losses were due to an incomplete, in-
correct, or missing telephone number or address. An-
other 16% of patients had moved from the address in
the patient file to an unknown location or distant loca-
tion. Among LTFU patients who were found alive, rea-
sons frequently cited for leaving the ART programs were
transfer to another program, cost of transport (financial
problems), and improved or deteriorating health. Less
common answers included stigma and social problems
and adverse events. In LTFU patients who died, 63% had
unrecorded causes of death, while another 23% died
from AIDS defining illnesses [61].
A cost analysis of preventing loss to follow up exam-
ined four specific interventions, with each subsequent
intervention increasing the costs. First, ART should be
provided for free to patients. The second incremental
intervention also eliminates the cost of patients for med-
ications that treat opportunistic infections. The third
intervention aims to improve HIV care skills among
health workers. The final intervention provides patients
with food during the day of visits for ART and cost of
transportation. The study found that these interventions,
if implemented with a success rate of retaining at least
12–41%, would be cost effective under when analyzed
using the Cost-Effectiveness of Preventing AIDS Com-
plications (CEPAC) International model [62].
Conclusions
This review explored the potential causes of preventable
in-hospital mortality associated with HIV infections in
sub-Saharan Africa in the anti-retroviral era. Based on
our experience as healthcare providers in Africa and a
review of the literature we identified 5 health systems
failures which may cause preventable in-hospital mortal-
ity, including late presentation of HIV cases, low rates of
in-hospital HIV testing, poor laboratory capacity which
limits CD4 T-cell testing and the diagnosis of opportun-
istic infections, delay in initiation of ART in-hospital,
and lastly, problems associated with loss to follow-up
upon discharge from hospital. Using our findings, along
with the current available literature, possible interven-
tions should be discussed and developed which may be
used to reduce in-hospital mortality.Abbreviations
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